Lupus Research Alliance News
Possible Cancer Drug 2DG May Boost Good Immune Cells

June 20, 2019 The investigational drug 2DG, tested as a cancer treatment, shows promise for lupus in new results reported by researchers from Japan at the European League Against Rheumatism (EULAR) 2019 annual meeting. Previous research had shown that the a potential drug, 2DG, increases the numbers of regulatory T cells, which turn down the […] READ MORE

NIH Work Co-Supported by LRA May Simplify Lupus Nephritis Monitoring

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […] READ MORE

$10 Million for Lupus Research Program Passed by House: Your Advocacy Works!

NEW YORK, NY. June 19, 2019. The U.S. House of Representatives today passed the Fiscal Year 2020 Defense Appropriations Act, which allocates the Lupus Research Alliance advocate’s full request for $10 million — double the current budget — for the Lupus Research Program in the Department of Defense’s (DoD) Congressionally Directed Medical Research Program. The […] READ MORE

LRA-Supported Discovery Highlighted at EULAR

June 19,2019 Partly funded by the Lupus Research Alliance, new results presented at the European Congress of Rheumatology (EULAR) 2019 suggest that some potential cancer treatments may also help patients with lupus.  Dr. Amr Sawalha of the University of Pittsburgh and colleagues have discovered a similarity between immune cells in lupus and some kinds of […] READ MORE

Remember During Men’s Health Month that Men Get Lupus Too

June 20, 2019 Michael Lauria knows only too well that lupus is not just a woman’s disease – he was diagnosed in the prime of his life – when he was just 32 years old. And he is counting on the Lupus Research Alliance to find the answers that will change his life. Young, fit, […] READ MORE

LRA’s 2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz

Boston, MA. June 19, 2019. The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients […] READ MORE

Gut Bacteria May Cause Antiphospholipid Syndrome, LRA-Funded Study Shows

June 18, 2019 A common type of bacteria living in the gut may spark a common lupus complication called antiphospholipid syndrome, a study partly funded by the Lupus Research Alliance shows. Antiphospholipid syndrome can lead to blood clots and miscarriages.  Led by Dr. Martin Alexander Kriegel of Yale School of Medicine, the research may also […] READ MORE

KZR-616 Shows Promise According to Results Reported at EULAR

Kezar Life Sciences announced positive results from the MISSION Phase 1 study testing the investigational KZR-616 as a treatment for lupus.  The presentation was at the European League Against Rheumatism (EULAR) 2019 annual meeting. The primary goal of the study was to assess if KZR-616 is safe and well tolerated. The study also looked at […] READ MORE

Stelara® Effective Over One Year and Reduces Severe Flares

Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over one year. Both highlight the benefit of ustekinumab on disease activity and the rate of severe flares. Ustekinumab reduced the rate of severe flares four times as much as placebo by week 24. The rate of […] READ MORE

Rituximab Effective for Maintenance Lupus Treatment Shows Study

June 13, 2019 A study published in Arthritis & Rheumatology found that rituximab was helpful as a maintenance therapy for tough-to-treat lupus patients. Maintenance treatment refers to one designed to help a main treatment work.  Rituximab is approved by the U.S. Food and Drug Administration for two types of cancer. It is sold by the […] READ MORE

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE

Learn and connect with our community!